Gilead discounts Sovaldi 99% for Egypt

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead (GILD) CEO John Martin's job convincing US legislators that Sovaldi's $84,000 domestic price is fair and reasonable just got a lot harder. It plans to sell the product to Egypt for $300/one-month box or $900 for a full three-month regimen.

Egypt has the world's highest prevalence of Hepatitis C due to the use of poorly sterilized needles in its decades-long campaign to eradicate schistosomiasis.